

# GETTING TO ACCESS

## *Innovative approaches to innovative medicines*

March 29, 2017

8:30 AM - 4:00 PM

SHERATON VANCOUVER WALL CENTRE

1088 Burrard Street, Vancouver, BC

## *Innovative Medicines Offer Opportunities and Challenges*

Why this forum matters: Innovative drug therapies are medicines that can:

- Offer a substantial improvement over existing therapies; for example, biologics can modify the underlying cause of a condition rather than just treat the symptoms;
- Address an unmet need; many drugs for rare disease are the first to be developed for that condition
- Target the (unique) characteristics of a subgroup of patients based on genetic makeup and/or other individual characteristics
- Cure the disease; for example, by eliminating the cause (hepatitis C virus), replacing abnormal cells (stem cell replacement), or modifying the faulty gene

**But innovative therapies come at a price that is often considered “unaffordable” under current assessment processes**

- Individually, therapies tend to be much higher than the “old” therapies they are replacing
- The number of innovative therapies is increasing, as is the impact on drug budgets
- Our assessment processes do not address innovation; they were developed to determine how much incremental cost should be paid for incremental benefits to existing therapies and how to allocate drug budgets to achieve most overall health of a population, regardless of the conditions and need
- Individual high-cost therapies can have an identifiable impact on overall drug plan budgets, whether private or public

## *What we will achieve at this forum?*

### **1. Identify options for access that work for all**

- Support managed access (criteria-based, monitored)
- Addresses key concerns of all stakeholder (timeliness, place in therapy, value, budget impact)
- Forward looking to best integrate future medicines (rare, personalized/targeted, stem cell and gene modification, repurposed, biosimilars)

### **2. Identify ways for all stakeholders to work collaboratively toward consensus approach**

- Identify what is working in current (Canadian) approaches and should be enhanced
- Identify what is getting in the way and strategies for addressing
- Identify areas of agreement (keep), disagreement (resolve), and ambiguity (clarify)
- Identify pathways to open communication, transparency, and engagement (of all stakeholders)

Presented by:



Canadian Organization  
for Rare Disorders

# DRAFT AGENDA

---

Pre-work:	<p>Readings</p> <ul style="list-style-type: none"> <li>Adaptive pathways</li> <li>Delphi: What constitutes good access agreement</li> </ul>	
8:30 a.m. – 9:00 a.m.	Breakfast and Registration	Junior Ballroom
9:00 a.m. – 9:15 a.m.	<p>Welcome and Objectives</p> <ul style="list-style-type: none"> <li>Why this, why now</li> </ul>	<p>Bill Dempster, 3Sixty Public Affairs</p> <p>Durhane Wong-Rieger, CORD</p>
9:15 a.m. – 9:45 a.m.	<p>Plenary: Hot Issues Affecting Innovative Access</p> <ul style="list-style-type: none"> <li>Time to Access: Too fast, too slow, or just right? (George Wyatt, Innomar Strategies)</li> <li>A Global Conundrum: Is Innovation Unaffordable? (TBC)</li> </ul>	
9:45 a.m. – 10:30 a.m.	<p>Plenary Panel: Drug development, pricing, and influencing factors (Carole Watson, Janssen; Kim Furlong, Amgen; BIOTECanada, pMPRB, TBC)</p> <ul style="list-style-type: none"> <li>Innovative therapies: today and tomorrow</li> <li>Pay for performance: Outcomes-based pricing</li> <li>To reference or not</li> </ul>	
10:30 a.m. – 10:45 a.m.	Refreshment Break	
10:45 a.m. – 12:00 p.m.	<p>Plenary Panel: Alternative pathways to innovative drug access</p> <p>Cathy Parker &amp; Michele Chadwick, Health Canada; Trevor Richter, CADTH; Tania Stafinski, University of Alberta; Fred Horne, Horne Associates; Nancy Worthington, Manulife; Angie Wong, Ontario Ministry of Health and Long-Term Care</p> <ul style="list-style-type: none"> <li>History of access (public and private): who, what, how, how effective</li> <li>Lifecycle approach, aka adaptive pathways, managed</li> </ul>	

	<p>access, coverage with evidence</p> <ul style="list-style-type: none"> <li>• Health Canada/CADTH/payers</li> <li>• International Approaches: ADAPTDSMART, NEWDIGGS, UK Highly Specialised Therapies</li> </ul>
12:00 p.m.– 1:00 p.m.	Lunch
1:00 p.m.– 2:00 p.m.	<p>Small Group Exercise: Perspective taking</p> <ul style="list-style-type: none"> <li>• Pharma price setting (Introduction: Kim Furlong, Amgen)</li> <li>• Payer budget management (Introduction: Sherry O’Quinn, MORSE Consulting)</li> </ul>
2:00 p.m.– 3:30 p.m.	<p>Small Group Exercise: Getting to access Facilitator: John-Paul Dowson, Roubaix Strategies</p> <ul style="list-style-type: none"> <li>• Right criteria: starting, stopping, monitoring</li> <li>• Right price: starting, value-based</li> <li>• Negotiation process</li> </ul>
3:30 p.m.– 4:00 p.m.	<p>Plenary: Outcomes</p> <ul style="list-style-type: none"> <li>• Learning</li> <li>• Next Steps</li> </ul>

# REGISTRATION

---

## **Individual Registration:**

- \$995 early bird rate (before March 12)
- \$1250 regular rate

## **Patient Registration:**

- \$495 early bird rate (before March 12)
- \$650 regular rate

PLEASE REGISTER ONLINE AT: <https://cofrd.wildapricot.org/event-2439509>

# CORPORATE SPONSORSHIP

---

If you have any questions, or wish to discuss a customized sponsorship package, please contact Angela at [angela@raredisorders.ca](mailto:angela@raredisorders.ca) or call (416) 969-7431 x 200